{"id":6468,"date":"2016-11-21T00:00:00","date_gmt":"2016-11-21T05:00:00","guid":{"rendered":"https:\/\/icesontario.wpengine.com\/journal-articles\/association-between-statin-use-and-ischemic-stroke-or-major-hemorrhage-in-patients-taking-dabigatran-for-atrial-fibrillation\/"},"modified":"2023-06-14T20:08:17","modified_gmt":"2023-06-15T00:08:17","slug":"association-between-statin-use-and-ischemic-stroke-or-major-hemorrhage-in-patients-taking-dabigatran-for-atrial-fibrillation","status":"publish","type":"journal_article","link":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/association-between-statin-use-and-ischemic-stroke-or-major-hemorrhage-in-patients-taking-dabigatran-for-atrial-fibrillation\/","title":{"rendered":"Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation"},"content":{"rendered":"<p><strong>Background<\/strong> &#x2014; Dabigatran etexilate is a pro-drug whose absorption is opposed by intestinal P-glycoprotein and which is converted by carboxylesterases to its active form, dabigatran. Unlike other statins, simvastatin and lovastatin are potent inhibitors of P-glycoprotein and carboxylesterase, and might either increase the risk of hemorrhage with dabigatran etexilate or decrease its effectiveness.<\/p>\n<p><strong>Methods<\/strong> &#x2014; We conducted two population-based, nested case-control studies of Ontario residents 66 years of age and older who initiated dabigatran etexilate between May 1, 2012 and March 31, 2014. In the first study, cases were subjects with ischemic stroke; in the second, cases were patients with major hemorrhage. Each case was matched with up to four controls on age and sex. All cases and controls received a single statin in the 60 days preceding the index date. We determined the association between each outcome and the use of simvastatin or lovastatin, relative to other statins.<\/p>\n<p><strong>Results<\/strong> &#x2014; Among 45,991 patients treated with dabigatran etexilate, we identified 397 cases with ischemic stroke and 1117 cases with hemorrhage. Following multivariable adjustment, use of simvastatin or lovastatin was not associated with an increased risk of stroke (adjusted odds ratio 1.33; 95% confidence interval 0.88 to 2.01). In contrast, simvastatin and lovastatin were associated with a higher risk of hemorrhage (adjusted odds ratio 1.46; 95% confidence interval 1.17 to 1.82). <\/p>\n<p><strong>Interpretation<\/strong> &#x2014; In patients receiving dabigatran etexilate, simvastatin and lovastatin are associated with a higher risk of hemorrhage relative to other statins. Preferential use of alternate agents may be advisable in these patients.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Background &#x2014; Dabigatran etexilate is a pro-drug whose absorption is opposed by intestinal P-glycoprotein and which is converted by carboxylesterases to its active form, dabigatran. Unlike other statins, simvastatin and lovastatin are potent inhibitors of P-glycoprotein and carboxylesterase, and might either increase the risk of hemorrhage with dabigatran etexilate or decrease its effectiveness. Methods &#x2014; [&hellip;]<\/p>\n","protected":false},"template":"","migration-helper-automated":[],"migration-manual":[],"topic":[40,56],"migration-helper-qa-sample-set":[],"class_list":["post-6468","journal_article","type-journal_article","status-publish","hentry","topic-cardiovascular-disease","topic-pharmacoepidemiology-and-drug-safety"],"acf":{"citation":"Antoniou T, Macdonald EM, Yao Z, Hollands S. Gomes T, Tadrous M, Mamdani MM, Juurlink DN; Canadian Drug Safety and Effectiveness Research Network. <em>CMAJ<\/em>. 2017; 184(1):E4-10. Epub 2016 Nov 21.","source_url":"http:\/\/www.cmaj.ca\/content\/early\/2016\/11\/21\/cmaj.160303","ices_scientist":[1386,1252,1282,1325,1108],"site":[6733],"research_program":[6746],"news_release":[7686],"journal_article":[],"atlas":[],"research_report":[],"infographic":[],"video":[],"downloads":null,"links":null,"sitecore_item_id":"8A115E8D-475A-415C-B727-E2EBFF823120","sitecore_item_name":"Association-between-statin-use-and-ischemic-stroke-or-major-hemorrhage-in-patients-taking-dabigatran","sitecore_field_values":"{\n  \"__Valid from\": \"20161125T152900\",\n  \"Title\": \"Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation\",\n  \"Short title\": \"Association between statin use and\",\n  \"Summary\": \"In patients receiving dabigatran etexilate, simvastatin and lovastatin are associated with a higher risk of hemorrhage relative to other statins.\",\n  \"Citation\": \"<p>Antoniou T, Macdonald EM, Yao Z, Hollands S. Gomes T, Tadrous M, Mamdani MM, Juurlink DN; Canadian Drug Safety and Effectiveness Research Network. <em>CMAJ<\/em>. 2017; 184(1):E4-10. Epub 2016 Nov 21.<\/p>\",\n  \"Abstract\": \"<p><strong>Background<\/strong> &mdash; Dabigatran etexilate is a pro-drug whose absorption is opposed by intestinal P-glycoprotein and which is converted by carboxylesterases to its active form, dabigatran. Unlike other statins, simvastatin and lovastatin are potent inhibitors of P-glycoprotein and carboxylesterase, and might either increase the risk of hemorrhage with dabigatran etexilate or decrease its effectiveness.<\/p>n<p><strong>Methods<\/strong> &mdash; We conducted two population-based, nested case-control studies of Ontario residents 66 years of age and older who initiated dabigatran etexilate between May 1, 2012 and March 31, 2014. In the first study, cases were subjects with ischemic stroke; in the second, cases were patients with major hemorrhage. Each case was matched with up to four controls on age and sex. All cases and controls received a single statin in the 60 days preceding the index date. We determined the association between each outcome and the use of simvastatin or lovastatin, relative to other statins.<\/p>n<p><strong>Results<\/strong> &mdash; Among 45,991 patients treated with dabigatran etexilate, we identified 397 cases with ischemic stroke and 1117 cases with hemorrhage. Following multivariable adjustment, use of simvastatin or lovastatin was not associated with an increased risk of stroke (adjusted odds ratio 1.33; 95% confidence interval 0.88 to 2.01). In contrast, simvastatin and lovastatin were associated with a higher risk of hemorrhage (adjusted odds ratio 1.46; 95% confidence interval 1.17 to 1.82). <\/p>n<p><strong>Interpretation<\/strong> &mdash; In patients receiving dabigatran etexilate, simvastatin and lovastatin are associated with a higher risk of hemorrhage relative to other statins. Preferential use of alternate agents may be advisable in these patients.<\/p>n<p><a href=\"http:\/\/www.cmaj.ca\/content\/early\/2016\/11\/21\/cmaj.160303\" title=\"External link opens\">View full text<\/a><\/p>\",\n  \"Keywords\": \"{119824F7-24C7-4BEC-A5CC-4699A1DB30E1}|{8B171BCD-F63E-4950-9C0D-FA00417F685C}|{8DA96C16-E06B-4D90-802D-73D8A7C9612E}\",\n  \"Related Products\": \"<h2>News Release<\/h2>rn<h3><a href=\"~\/link.aspx?_id=2BC91A06A4994952BB75FC7360F06E36&amp;_z=z\">Study finds risk of hemorrhage with combination of two common statins and stroke prevention drug<\/a><\/h3>rn<h2>ICES in the news<\/h2>rn<h3><a href=\"http:\/\/www.foxnews.com\/health\/2016\/11\/22\/drug-combo-may-cause-bleeding-for-patients-with-irregular-heartbeat.html\" title=\"Fox News\" target=\"_blank\">Drug combo may cause bleeding for patients with irregular heartbeat <\/a><\/h3>\",\n  \"Research Programs\": \"{CFE36C89-C969-4C23-B5E4-1BA9E5BDC273}\",\n  \"ICES Locations\": \"{4FCAABBA-14A5-42E6-8F33-BC6C2F1D9908}\",\n  \"ICES Scientists\": \"{4FE84877-EBF5-4E0E-88AA-82F7AEB2DE79}|{1FA4634A-81DF-4A25-8739-98ABF3872B45}|{5268F1B0-EB3E-4577-93DF-3C70C9399847}|{F2F916BC-2EE9-4C65-BCAB-086ED6BB971A}|{57F695DB-AAD1-46E5-829F-5BAB09CF881B}\",\n  \"Posted Date\": \"20161121T093500\",\n  \"Show on Publications Landing Page\": \"1\"\n}","previous_url":"https:\/\/www.ices.on.ca\/Publications\/Journal-Articles\/2016\/January\/Association-between-statin-use-and-ischemic-stroke-or-major-hemorrhage-in-patients-taking-dabigatran"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ICES | Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation<\/title>\n<meta name=\"description\" content=\"Background &#x2014; Dabigatran etexilate is a pro-drug whose absorption is opposed by intestinal P-glycoprotein and which is converted by\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/association-between-statin-use-and-ischemic-stroke-or-major-hemorrhage-in-patients-taking-dabigatran-for-atrial-fibrillation\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ICES | Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation\" \/>\n<meta property=\"og:description\" content=\"Background &#x2014; Dabigatran etexilate is a pro-drug whose absorption is opposed by intestinal P-glycoprotein and which is converted by\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/association-between-statin-use-and-ischemic-stroke-or-major-hemorrhage-in-patients-taking-dabigatran-for-atrial-fibrillation\/\" \/>\n<meta property=\"og:site_name\" content=\"ICES\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ICESOntario\/\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-15T00:08:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/association-between-statin-use-and-ischemic-stroke-or-major-hemorrhage-in-patients-taking-dabigatran-for-atrial-fibrillation\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/association-between-statin-use-and-ischemic-stroke-or-major-hemorrhage-in-patients-taking-dabigatran-for-atrial-fibrillation\\\/\",\"name\":\"ICES | Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\"},\"datePublished\":\"2016-11-21T05:00:00+00:00\",\"dateModified\":\"2023-06-15T00:08:17+00:00\",\"description\":\"Background &#x2014; Dabigatran etexilate is a pro-drug whose absorption is opposed by intestinal P-glycoprotein and which is converted by\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/association-between-statin-use-and-ischemic-stroke-or-major-hemorrhage-in-patients-taking-dabigatran-for-atrial-fibrillation\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/association-between-statin-use-and-ischemic-stroke-or-major-hemorrhage-in-patients-taking-dabigatran-for-atrial-fibrillation\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/association-between-statin-use-and-ischemic-stroke-or-major-hemorrhage-in-patients-taking-dabigatran-for-atrial-fibrillation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Journal Articles\",\"item\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/publications\\\/journal-articles\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"name\":\"ICES\",\"description\":\"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\"},\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#organization\",\"name\":\"ICES\",\"alternateName\":\"Institute for Clinical Evaluative Sciences\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"contentUrl\":\"https:\\\/\\\/www.ices.on.ca\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/ices-logo.png\",\"width\":\"676\",\"height\":\"618\",\"caption\":\"ICES\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ices.on.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ICESOntario\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ices-research-institute\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ICES | Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation","description":"Background &#x2014; Dabigatran etexilate is a pro-drug whose absorption is opposed by intestinal P-glycoprotein and which is converted by","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/association-between-statin-use-and-ischemic-stroke-or-major-hemorrhage-in-patients-taking-dabigatran-for-atrial-fibrillation\/","og_locale":"fr_FR","og_type":"article","og_title":"ICES | Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation","og_description":"Background &#x2014; Dabigatran etexilate is a pro-drug whose absorption is opposed by intestinal P-glycoprotein and which is converted by","og_url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/association-between-statin-use-and-ischemic-stroke-or-major-hemorrhage-in-patients-taking-dabigatran-for-atrial-fibrillation\/","og_site_name":"ICES","article_publisher":"https:\/\/www.facebook.com\/ICESOntario\/","article_modified_time":"2023-06-15T00:08:17+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2024\/11\/ic-es-data-discovery-better-health-logo.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/association-between-statin-use-and-ischemic-stroke-or-major-hemorrhage-in-patients-taking-dabigatran-for-atrial-fibrillation\/","url":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/association-between-statin-use-and-ischemic-stroke-or-major-hemorrhage-in-patients-taking-dabigatran-for-atrial-fibrillation\/","name":"ICES | Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation","isPartOf":{"@id":"https:\/\/www.ices.on.ca\/fr\/#website"},"datePublished":"2016-11-21T05:00:00+00:00","dateModified":"2023-06-15T00:08:17+00:00","description":"Background &#x2014; Dabigatran etexilate is a pro-drug whose absorption is opposed by intestinal P-glycoprotein and which is converted by","breadcrumb":{"@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/association-between-statin-use-and-ischemic-stroke-or-major-hemorrhage-in-patients-taking-dabigatran-for-atrial-fibrillation\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/association-between-statin-use-and-ischemic-stroke-or-major-hemorrhage-in-patients-taking-dabigatran-for-atrial-fibrillation\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/association-between-statin-use-and-ischemic-stroke-or-major-hemorrhage-in-patients-taking-dabigatran-for-atrial-fibrillation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ices.on.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Journal Articles","item":"https:\/\/www.ices.on.ca\/fr\/publications\/journal-articles\/"},{"@type":"ListItem","position":3,"name":"Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation"}]},{"@type":"WebSite","@id":"https:\/\/www.ices.on.ca\/fr\/#website","url":"https:\/\/www.ices.on.ca\/fr\/","name":"ICES","description":"POPULATION-BASED HEALTH RESEARCH THAT MAKES A DIFFERENCE","publisher":{"@id":"https:\/\/www.ices.on.ca\/fr\/#organization"},"alternateName":"Institute for Clinical Evaluative Sciences","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ices.on.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ices.on.ca\/fr\/#organization","name":"ICES","alternateName":"Institute for Clinical Evaluative Sciences","url":"https:\/\/www.ices.on.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","contentUrl":"https:\/\/www.ices.on.ca\/wp-content\/uploads\/2023\/04\/ices-logo.png","width":"676","height":"618","caption":"ICES"},"image":{"@id":"https:\/\/www.ices.on.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ICESOntario\/","https:\/\/www.linkedin.com\/company\/ices-research-institute\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article\/6468","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/journal_article"}],"about":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/types\/journal_article"}],"acf:post":[{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/news_release\/7686"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/research_program\/6746"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/site\/6733"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1108"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1325"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1282"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1252"},{"embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/ices_scientist\/1386"}],"wp:attachment":[{"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/media?parent=6468"}],"wp:term":[{"taxonomy":"migration-helper-automated","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-automated?post=6468"},{"taxonomy":"migration-manual","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-manual?post=6468"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/topic?post=6468"},{"taxonomy":"migration-helper-qa-sample-set","embeddable":true,"href":"https:\/\/www.ices.on.ca\/fr\/wp-json\/wp\/v2\/migration-helper-qa-sample-set?post=6468"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}